CVS plans to separate its retail pharmacy business by 2028
CVS plans to split into two publicly traded companies by the first half of 2028. CVS Health will retain Aetna, Caremark and other healthcare businesses, while CVS Pharmacy will include about 9,000 stores and related operations. Shareholders are expected to receive shares in both companies, subject to approvals and other conditions.
CVS expects Health Services earnings to trough in 2027
CVS Health expects its Health Services segment to hit an earnings low in 2027, with adjusted operating income of at least $7 billion amid 340B declines, a weaker selling season and client membership losses. The segment returned to growth in 2025 and is expected to grow again after 2027. Company-wide adjusted EPS is forecast at $8.65 or more in 2027.
Zacks cites Aetna recovery and PBM pressures in CVS stock outlook
CVS's recovery case is improving as Aetna's third-quarter 2026 adjusted operating income rose to $912 million and its medical benefit ratio improved to 91.3%. Stronger cash flow supported debt repayment and plans to resume buybacks. Persistent PBM, reimbursement and membership pressures weigh on the outlook, while management expects further Aetna margin improvement in 2027.
Zacks assigns CVS a Rank #2 (Buy) in its trending-stock review
CVS shares gained 1.7% over the past month, outperforming the S&P 500 but trailing its industry. Zacks assigns CVS a Rank #2 (Buy), citing earnings estimate revisions: current-year and next-year estimates rose 2.9% and 1.5% over the past month, though the current-quarter estimate fell 11.9%. CVS beat revenue and EPS expectations in each of the past four quarters.
CVS Health was upgraded to Zacks Rank #2 (Buy) after its consensus earnings estimate for fiscal 2026 rose 2.8% over the past three months to $8.17 per share, flat year over year. Zacks says the upgrade reflects improving earnings expectations that may support near-term share-price gains.
CVS Caremark expands its use of lower-cost biosimilars
CVS Caremark says its biosimilar strategy is expanding access to lower-cost treatments while preserving clinical standards. The company reports approximately $3.3 billion in gross savings for clients and members from its approach. It is accelerating biosimilar adoption, removing Humira from many client formularies and shifting Stelara coverage toward lower-cost biosimilars as they become available.
CVS challenges Tennessee’s pharmacy benefit manager ownership ban
CVS Health has sued in federal court to challenge Tennessee’s law barring pharmacies from owning pharmacy benefit managers. The dispute targets CVS’s integrated pharmacy and PBM model and follows its plan to separate those operations into two companies. CVS says Tennessee patients’ pharmacy services will continue without interruption as the case proceeds. The outcome could affect how CVS operates in the state.
CVS Health shares have gained 38.7% over three years but recently pulled back, closing at $83.85 as the company plans to split into retail pharmacy and insurance/healthcare services businesses in 2028. The stock trades at 9.7 times earnings, below healthcare industry and peer averages of 24.9 and 20.3, respectively. The valuation outlook remains subject to the planned breakup and legal disputes over Medicare Advantage ratings.
CVS reports $108.4 billion in revenue and raises its 2026 outlook
CVS Health reported third-quarter revenue of $108.4 billion, up 5.4% year over year, and adjusted earnings of $2.09 per share, beating estimates. The company raised its 2026 adjusted EPS guidance to at least $8.20 and operating cash flow guidance to at least $15.5 billion. Health Care Benefits operating income improved, while pharmacy reimbursement pressure and elevated medical costs remained concerns.
Yahoo Finance Video reports CVS has dropped retail spin-off plans
CVS reversed course on its $70 billion Aetna merger strategy, abandoning plans to spin off its retail business as it reassesses its business model and the future of its pharmacy and insurance operations.